中国医药生物技术
中國醫藥生物技術
중국의약생물기술
CHINESE MEDICINAL BIOTECHNOLOGY
2012年
6期
426-429
,共4页
糖尿病,2 型%周围神经系统疾病%胰岛素样生长因子 I%胰岛素样生长因子结合蛋白质 3
糖尿病,2 型%週圍神經繫統疾病%胰島素樣生長因子 I%胰島素樣生長因子結閤蛋白質 3
당뇨병,2 형%주위신경계통질병%이도소양생장인자 I%이도소양생장인자결합단백질 3
Diabetes mellitus, type 2%Peripheral nervous system diseases%Insulin-like growth factor I%Insulin-like growth factor binding protein 3
目的探讨外周血 IGF-1和 IGFBP-3在2型糖尿病周围神经病诊断中的意义.
方法研究对象分为2型糖尿病周围神经病组、2型糖尿病无周围神经病组和健康人群组3组,以化学发光法检测血清中 IGF-1和 IGFBP-3水平.
结果 IGF-1和 IGFBP-3水平在周围神经病组[IGF-1:(132.65±50.78)ng/ml;IGFBP-3:(3.43±1.05)μg/ml]明显低于无周围神经病组[IGF-1:(160.25±66.13)ng/ml;IGFBP-3:(4.37±1.35)μg/ml)]和健康对照组[IGF-1:(174.95±64.38)ng/ml;IGFBP-3:(4.75±3.39)μg/ml](P<0.05),而后两组间无统计学差异(P>0.05).
结论 IGF-1和 IGFBP-3水平减少与 2型糖尿病周围神经病的发生相关,对两者的监测有利于 2型糖尿病周围神经病的诊断.
目的探討外週血 IGF-1和 IGFBP-3在2型糖尿病週圍神經病診斷中的意義.
方法研究對象分為2型糖尿病週圍神經病組、2型糖尿病無週圍神經病組和健康人群組3組,以化學髮光法檢測血清中 IGF-1和 IGFBP-3水平.
結果 IGF-1和 IGFBP-3水平在週圍神經病組[IGF-1:(132.65±50.78)ng/ml;IGFBP-3:(3.43±1.05)μg/ml]明顯低于無週圍神經病組[IGF-1:(160.25±66.13)ng/ml;IGFBP-3:(4.37±1.35)μg/ml)]和健康對照組[IGF-1:(174.95±64.38)ng/ml;IGFBP-3:(4.75±3.39)μg/ml](P<0.05),而後兩組間無統計學差異(P>0.05).
結論 IGF-1和 IGFBP-3水平減少與 2型糖尿病週圍神經病的髮生相關,對兩者的鑑測有利于 2型糖尿病週圍神經病的診斷.
목적탐토외주혈 IGF-1화 IGFBP-3재2형당뇨병주위신경병진단중적의의.
방법연구대상분위2형당뇨병주위신경병조、2형당뇨병무주위신경병조화건강인군조3조,이화학발광법검측혈청중 IGF-1화 IGFBP-3수평.
결과 IGF-1화 IGFBP-3수평재주위신경병조[IGF-1:(132.65±50.78)ng/ml;IGFBP-3:(3.43±1.05)μg/ml]명현저우무주위신경병조[IGF-1:(160.25±66.13)ng/ml;IGFBP-3:(4.37±1.35)μg/ml)]화건강대조조[IGF-1:(174.95±64.38)ng/ml;IGFBP-3:(4.75±3.39)μg/ml](P<0.05),이후량조간무통계학차이(P>0.05).
결론 IGF-1화 IGFBP-3수평감소여 2형당뇨병주위신경병적발생상관,대량자적감측유리우 2형당뇨병주위신경병적진단.
Objective To investigate the significance of insulin-like growth factor I ( IGF-1) and I insulin-like growth factor binding protein 3 (GFBP-3) in diagnosis of type 2 diabetic peripheral neuropathy. @@@@Methods By means of chemiluminescent assay, we detected the content of IGF-1 and IGFBP-3 in sera of experiment subjects. The experimental subjects were divided into three groups, including type 2 diabetic peripheral neuropathy group (DPN group), type 2 diabetes mellitus without peripheral neuropathy group (DM group) and health group. @@@@Results The DPN group had significantly lower levels of IGF-1 and IGFBP-3 [IGF-1:(132.65 ± 50.78) ng/ml;IGFBP-3:(3.43 ± 1.05)μg/ml] compared to either DM group [IGF-1:(160.25 ± 66.13) ng/ml;IGFBP-3:(4.37 ± 1.35)μg/ml] or health group [IGF-1:(174.95 ± 64.38) ng/ml; IGFBP-3: (4.75 ± 3.39) μg/ml] (P < 0.05). No significant difference was found between DM group and health group (P>0.05). @@@@Conclusion Decreased levels of IGF-1 and IGFBP-3 in diabetic patients play a role in the occurrence of peripheral neuropathy. It will be helpful to monitor IGF-1 and IGFBP3 levels in the diagnosis of this disease.
